BioInvent International AB (publ) (STO:BINV)
27.50
+1.85 (7.21%)
May 22, 2026, 5:29 PM CET
BioInvent International AB Employees
BioInvent International AB had 112 employees as of March 31, 2026. The number of employees decreased by 6 or -5.08% compared to the same quarter last year.
Employees
112
Change
-6
Growth
-5.08%
Revenue / Employee
1.95M SEK
Profits / Employee
-3.00M SEK
Market Cap
1.81B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 112 | -6 | -5.08% |
| Dec 31, 2025 | 109 | -5 | -4.39% |
| Sep 30, 2025 | 124 | 9 | 7.83% |
| Jun 30, 2025 | 122 | 10 | 8.93% |
| Mar 31, 2025 | 118 | 9 | 8.26% |
| Dec 31, 2024 | 114 | 3 | 2.70% |
| Sep 30, 2024 | 115 | 7 | 6.48% |
| Jun 30, 2024 | 112 | 9 | 8.74% |
| Mar 31, 2024 | 109 | 7 | 6.86% |
| Dec 31, 2023 | 111 | 17 | 18.09% |
| Sep 30, 2023 | 108 | 15 | 16.13% |
| Jun 30, 2023 | 103 | 14 | 15.73% |
| Mar 31, 2023 | 102 | 16 | 18.60% |
| Dec 31, 2022 | 94 | 10 | 11.90% |
| Sep 30, 2022 | 93 | 8 | 9.41% |
| Jun 30, 2022 | 89 | 11 | 14.10% |
| Mar 31, 2022 | 86 | 12 | 16.22% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Hansa Biopharma AB | 122 |
| Egetis Therapeutics AB | 44 |
| Vicore Pharma Holding AB | 37 |
| Genovis AB (publ.) | 36 |
| Saniona AB | 31 |
| Xspray Pharma AB | 24 |
| Cantargia AB | 22 |
| Medivir AB | 10 |
BioInvent International AB News
- 4 days ago - BioInvent to Host Virtual KOL Event to Discuss BI-1808 for the Treatment of Ovarian Cancer, on May 27, 2026 - Accesswire
- 25 days ago - Resolutions at BioInvent's Annual General Meeting 2026 - Accesswire
- 25 days ago - BioInvent International AB Quarterly report: Q1 2026 - Filings
- 25 days ago - BioInvent to Host Two Key Opinion Leader Events Highlighting Progress Across Oncology Portfolio - Accesswire
- 25 days ago - BioInvent International AB: Interim Report January - March 2026 - Accesswire
- 4 weeks ago - BioInvent to Present Data of BI-1808 Plus KEYTRUDA(R) (Pembrolizumab) in Recurrent Ovarian Cancer at the 2026 ASCO Annual Meeting - Accesswire
- 7 weeks ago - BioInvent International AB Publishes Annual Report 2025 - Accesswire
- 2 months ago - BioInvent Achieves Phase 3 Milestone for HMI-115 in Endometriosis - Accesswire